X.T.L. Biopharmaceuticals Partners with NCCS to Advance CAR-T Therapy for Solid Tumors

Elpis Biopharmaceuticals Partners with NCCS to Advance CAR-T Therapy for Solid Tumors

Elpis Biopharmaceuticals, a clinical-stage cell therapy innovator, has entered a pivotal partnership with the National Cancer Centre Singapore (NCCS) as outlined in a Memorandum of Understanding (MOU) signed on July 27, 2025. This collaboration aims to propel Elpis's armored CAR-T technologies into first-in-human trials, specifically targeting aggressive malignancies such as colorectal, pancreatic, and ovarian cancers. Currently, CAR-T cell therapies are predominantly approved for treating hematological cancers, and this venture represents a strategic effort to broaden their applications to solid tumors, which pose significant treatment challenges.

Under this partnership, Elpis will leverage its cutting-edge technologies, including multi-mechanism armor and bispecific targeting antibodies, alongside cytokine cocktails and a rapid mRNA display discovery engine. These innovations are already under evaluation in ongoing global clinical trials, specifically EPC-002 and EPC-003. The establishment of laboratory space at NCCS will further enhance this collaboration, allowing for the sharing of equipment and expertise, which is critical for streamlining research and development phases. Dr. Yan Chen, Founder and CEO of Elpis, articulates the partnership's importance by stating, "This partnership reflects our commitment to rapidly advancing innovative immunotherapies," underlining the company’s mission to expedite life-saving treatments from discovery to regulatory approval.

The collaboration with NCCS is not only a strategic move for Elpis Biopharmaceuticals but also a significant advancement in the field of cancer therapy. By combining Elpis's innovative technologies with NCCS's clinical research capabilities, the partnership aims to transition advanced cell therapies from laboratory settings into practical, clinical applications. With the potential to deliver groundbreaking treatments to patients in Singapore and beyond, this initiative marks a substantial step forward in the ongoing battle against cancer, promising new hope for patients afflicted by hard-to-treat solid tumors.

In addition to this major partnership, Elpis continues to focus on enhancing its global clinical trial infrastructure. The collaboration with NCCS is anticipated to provide critical insights and data that could influence future trials and therapeutic strategies. As the biopharmaceutical landscape evolves, partnerships like this one exemplify the commitment to innovation and the urgency of addressing unmet medical needs in oncology. Elpis's approach highlights the importance of combining technology with clinical expertise to achieve transformative outcomes in cancer treatment.